Ozanimod

Data Sheet For research use only. Not for human use.

Cat. No. ：BCP16513CAS No. ：1306760-87-1Purity：98%

Get Quotation Now

Tel: 0086-17754423994 or orders@biochempartner.com

* Required Fields.

Please complete the form below and you will get the price list in 1 minute.

* Required Fields.

Please complete the form below and we will contact you shortly.

* Required Fields.

Please complete the form below and we will contact you shortly.

CAS No.	1306760-87-1	Cat. No.	BCP16513
Related Products	1618636-37-5（Ozanimod hydrochloride）
Name	Ozanimod
Synonyms	RPC1063; RPC-1063; RPC 1063;
SMILES
Chemical Name
Formula	C23H24N4O3	M. Wt	404.46
Purity	98%	Storage	Store at 4-8°C
Description	Target: sphingosine 1-phosphate 1 and 5 receptor Ozanimod represents a potential franchise in immunology. Ozanimod is the potential next-to-market oral agent for the treatment of relapsing multiple sclerosis. In a Phase 2 trial in patients with RMS, Ozanimod achieved the primary endpoint of reduction in MRI brain lesion activity as well as secondary endpoints measuring effects on other MRI parameters. The overall safety profile of Ozanimod is consistent with the results of prior trials and continues to demonstrate differentiation against other oral agents for treatment of RMS. Ozanimod is also being studied in inflammatory bowel disease (IBD). The TOUCHSTONE Phase 2 trial of Ozanimod in UC met its primary endpoint and all secondary endpoints with statistical significance in patients on the 1.0 mg dose of Ozanimod in the 8-week induction period. The overall safety and tolerability profile of Ozanimod is consistent with the results of the recent Phase 2 trial in RMS, and continues to sup